These findings are in agreement with reports suggesting GLP-1 receptor agonists and SGLT2 inhibitors reduce hepatic steatosis by attenuating insulin resistance and hepatic fat accumulation [19]. This evidence concerns the gene SLC5A2 and fatty liver disease.